Adma Biologics (ADMA) Other financing activities (2012 - 2025)

Adma Biologics has reported Other financing activities for 8 years, with the latest figure at -$2.2 million in Q4 2025.

• For the quarter ending Q4 2025, Other financing activities changed N/A year-over-year to -$2.2 million; the trailing twelve-month figure through Dec 2025 stood at $127000.0 (down 94.6% YoY), and the FY2023 full-year result was $2.4 million, down 15.52% from the prior year.
• Other financing activities for Q4 2025 stood at -$2.2 million, down from $2.4 million in the prior quarter.
• The five-year high for Other financing activities was $2.4 million in Q1 2022, with the low at -$2.2 million in Q4 2025.
• Historically, Other financing activities has averaged $582000.0 across 3 years, with a median of $404562.0 in 2022.
• The largest YoY upside for Other financing activities was 3265177.78% in 2023 against a maximum downside of 3265177.78% in 2023.
• Adma Biologics' Other financing activities stood at $72.0 in 2022, then surged by 3265177.78% to $2.4 million in 2023, then sank by 194.6% to -$2.2 million in 2025.
• The last three Other financing activities figures came in at -$2.2 million (Q4 2025), $2.4 million (Q4 2023), and $72.0 (Q4 2022), per Business Quant data.